Novo Nordisk NOVO.B1.83%increase; up pointing triangle has signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion. The Danish ...

We have already seen results from some of ribupatide's studies, including those conducted in China. And so far, it looks promising. Kailera's pipeline also includes KAI-7535, an investigational oral ...

Novo Nordisk trades at a discount to sector earnings multiples but appears expensive on free cash flow due to elevated capex. Management's guidance to normalize capex by 2030 is pivotal; free cash ...

On Sept. 24, Novo announced an agreement with Nanexa, a drug delivery company based in Sweden. As part of the deal, Nanexa will license its proprietary PharmaShell long-acting drug-delivery technology ...

Novo Nordisk has more than 1.5 million people on the Wegovy pill globally as its popularity remains strong. Globally, more than 46 million people are on obesity and diabetes treatments, showing the ...

Novo set to pay Hengrui up to $2.6 billion for rights to pill China develops nearly 250 experimental treatments Hengrui candidate shows potential for once-weekly dosage The deal helps Novo shore up ...

“Like any business, Novo regularly evaluates its organization to ensure we are positioned to meet evolving market dynamics and patient needs,” a company spokesperson said in a statement confirming the ...

The delay comes down to issues the FDA uncovered during a pre-license inspection of Novo’s Frehemgo manufacturing site after its review submission last fall. (iStock/Getty Images Plus) Already ...

Oct 2 (Reuters) - The US FDA has extended its review of Novo Nordisk's (NOVOb.CO), opens new tab experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, ‌the Danish ...

HRS-1596 could “substantially reduce dosing frequency and improve convenience compared with current offerings,” Novo suggested. (Novo Nordisk) Novo’s ongoing attempts to rejuvenate its pipeline have ...